Effects of Spironolactone Combination Therapy on Proteinuria, Kidney Function, and Blood Pressure

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 136 participants.

Also called NCT01667614

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 136 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01667614
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Iran (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01667614. Randomized; no masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2012-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effects of Spironolactone Combination Therapy on Proteinuria, Kidney Function, and Blood Pressure
Condition
Type 2 Diabetes Mellitus
Condition
Diabetic Nephropathy
Condition
Essential Hypertension
Intervention (Drug)
spironolacone 25 mg tablets added to losartan
Lead sponsor
Tehran University of Medical Sciences (class: other)

Record details

Record id
cardio:ct-nct01667614
Content hash
451055bcd831737052c04e7f16663cd3900e3fa07da3485efd4cceb150126fac